Quarterly ResultMay 1, 2026, 04:15 PM
Moderna Q1 Revenue Jumps to $389M; Net Loss Widens to $1.34B
AI Summary
Moderna reported a significant increase in total revenue for the first quarter of 2026, reaching $389 million, primarily driven by a surge in net product sales to $352 million. However, the company's net loss widened to $1.34 billion, or $(3.40) per share, compared to a net loss of $(971) million in the same period last year. The quarter also saw a new collaboration agreement with Recordati for an investigational propionic acidemia therapeutic, including a $50 million upfront payment.
Key Highlights
- Total revenue increased to $389 million, up from $108 million year-over-year.
- Net product sales surged to $352 million, compared to $86 million in prior year.
- Net loss widened to $1.34 billion, or $(3.40) per share, from $(971) million.
- Entered collaboration with Recordati for mRNA-3927, receiving a $50 million upfront payment.
- COVID vaccine sales reached $345 million, up from $84 million.
- RSV vaccine sales were $7 million, up from $2 million.
- Net cash used in operating activities was $(630) million, an improvement from $(1,037) million.
- Cash and cash equivalents stood at $1.91 billion as of March 31, 2026.